Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $8.00 Consensus Price Target from Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been given a consensus recommendation of “Buy” by the five brokerages that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.00.

HOWL has been the topic of a number of research analyst reports. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. JMP Securities reduced their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Finally, Bank of America cut their target price on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, August 25th.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in HOWL. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics during the second quarter worth $409,000. Marshall Wace LLP acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at approximately $113,000. Y Intercept Hong Kong Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at approximately $92,000. Deutsche Bank AG raised its holdings in shares of Werewolf Therapeutics by 450.7% in the fourth quarter. Deutsche Bank AG now owns 101,626 shares of the company’s stock valued at $150,000 after purchasing an additional 83,172 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics in the first quarter valued at approximately $79,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock opened at $1.84 on Friday. The stock’s 50-day moving average is $1.34 and its two-hundred day moving average is $1.15. Werewolf Therapeutics has a fifty-two week low of $0.60 and a fifty-two week high of $4.18. The firm has a market cap of $84.14 million, a P/E ratio of -1.12 and a beta of 0.64. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.10. Analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.